Advertisement

Breast Cancer

, Volume 19, Issue 2, pp 118–124 | Cite as

The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis

  • Takeshi ImamuraEmail author
  • Atsuhiko Hikita
  • Yasumichi Inoue
Special Feature Should we treat minimal breast cancer lesions?

Abstract

Transforming growth factor-β (TGF-β) ligand is a multifunctional growth factor that regulates various cell behavior, such as cell proliferation, differentiation, migration, and apoptosis. Because TGF-β is a potent growth inhibitor, abnormalities in TGF-β signaling result in carcinogenesis. In addition to tumor suppressor function, TGF-β acts as an oncogenic factor. In particular, TGF-β signaling plays an important role during metastasis of breast cancer. Recently, epithelial-mesenchymal transition (EMT) has been shown to confer malignant properties such as cell motility and invasiveness to cancer cells and plays crucial roles during cancer metastasis. Moreover, breast stem-like cells exhibit EMT properties. Because TGF-β is a potent regulator of EMT as well as cell stemness, TGF-β signaling might play a crucial role in the regulation of breast cancer stem cells.

Keywords

TGF-β Breast cancer Metastasis Cancer stem cell 

Notes

Acknowledgments

There are many important papers in this field, and for reasons of space, we have not been able to mention all of them. We apologize to those investigators whose papers could not be cited. This work was supported by KAKENHI (Grants-in-Aid for Scientific Research) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. T.I. was supported by the Takeda Science Foundation.

References

  1. 1.
    Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12:22–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Bierie B, Moses HL. TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–49.PubMedCrossRefGoogle Scholar
  6. 6.
    Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene. 2008;27:6322–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133:66–77.PubMedCrossRefGoogle Scholar
  8. 8.
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197–206.PubMedCrossRefGoogle Scholar
  10. 10.
    Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Inoue Y, Imamura T. Regulation of TGF-β family signaling by E3 ubiquitin ligases. Cancer Sci. 2008;99:2107–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Ikushima H, Miyazono K. Cellular context-dependent “colors” of transforming growth factor-beta signaling. Cancer Sci. 2010;101:306–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells. 2002;7:1191–204.PubMedCrossRefGoogle Scholar
  14. 14.
    Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell. 1997;89:1165–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, et al. Smad6 inhibits signalling by the TGF-β superfamily. Nature. 1997;389:622–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, et al. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun. 1998;244:26–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Hanyu A, Ishidou Y, Ebisawa T, Shimanuki T, Imamura T, Miyazono K. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. J Cell Biol. 2001;155:1017–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Seoane J, Le HV, Shen L, Anderson SA, Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117:211–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Gomis RR, Alarcón C, Nadal C, Van Poznak C, Massagué J. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006;10:203–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-β. EMBO J. 2000;19:5178–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Pardali K, Kurisaki A, Morén A, ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21Waf1/Cip1 regulation by transforming growth factor-β. J Biol Chem. 2000;275:29244–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M, et al. ChIP-chip analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in TGF-β signaling. Mol Cell Biol. 2009;29:172–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen CR, Kang Y, Siegel PM, Massagué J. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell. 2002;110:19–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem. 2002;277:854–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Seoane J, Le H-V, Massagué J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002;419:729–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3:392–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol. 2001;3:400–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 2005;5:603–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Kang Y, Chen CR, Massagué J. A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003;11:915–26.PubMedCrossRefGoogle Scholar
  30. 30.
    Valderrama-Carvajal H, Cocolakis E, Lacerte A, Lee EH, Krystal G, Ali S, et al. Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol. 2002;4:963–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Ribeiro A, Bronk SF, Roberts PJ, Urrutia R, Gores GJ. The transforming growth factor β1-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology. 1999;30:1490–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Wildey GM, Patil S, Howe PH. Smad3 potentiates transforming growth factor β (TGFβ)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes. J Biol Chem. 2003;278:18069–77.PubMedCrossRefGoogle Scholar
  33. 33.
    Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGF-β induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol. 2002;4:51–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001;28:184–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Liang M, Liang YY, Wrighton K, Ungermannova D, Wang XP, Brunicardi FC, et al. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Mol Cell Biol. 2004;24:7524–37.PubMedCrossRefGoogle Scholar
  37. 37.
    Deheuninck J, Luo K. Ski and SnoN, poent negative regulators of TGF-β signaling. Cell Res. 2009;19:47–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol. 2007;27:6068–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood. 1998;92:4003–12.PubMedGoogle Scholar
  40. 40.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.PubMedCrossRefGoogle Scholar
  42. 42.
    Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Hurd TW, Gao L, Roh MH, Macara IG, Margolis B. Direct interaction of two polarity complexes implicated in epithelial tight junction assembly. Nat Cell Biol. 2003;5:137–42.PubMedCrossRefGoogle Scholar
  45. 45.
    Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity. Science. 2005;307:1603–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10:2462–77.PubMedCrossRefGoogle Scholar
  47. 47.
    Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol. 2002;156:299–313.PubMedCrossRefGoogle Scholar
  48. 48.
    Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFβ-induced downregulation of E-cadherin-based cell–cell adhesion depends on PI3-kinase and PTEN. J Cell Sci. 2005;118:4901–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Horiguchi K, Shirakihara T, Nakano A, Imamura T, Miyazono K, Saitoh M. Role of Ras signaling in the induction of Snail by transforming growth factor-β. J Biol Chem. 2009;284:245–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, et al. TGF-β1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest. 2010;120:290–302.PubMedCrossRefGoogle Scholar
  51. 51.
    Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res. 2002;17:1667–79.PubMedCrossRefGoogle Scholar
  52. 52.
    Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res. 2006;66:6714–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res. 2006;12:4315–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 2007;98:127–33.PubMedCrossRefGoogle Scholar
  55. 55.
    Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.PubMedCrossRefGoogle Scholar
  56. 56.
    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.PubMedCrossRefGoogle Scholar
  59. 59.
    Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–9.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2011

Authors and Affiliations

  • Takeshi Imamura
    • 1
    • 2
    Email author
  • Atsuhiko Hikita
    • 1
    • 2
  • Yasumichi Inoue
    • 3
  1. 1.Department of Molecular Medicine for PathogenesisEhime University Graduate School of MedicineToonJapan
  2. 2.Core Research for Evolutional Science and Technology (CREST)Japan Science and Technology Agency (JST)ToonJapan
  3. 3.Department of Drug Metabolism and Disposition, Graduate School of Pharmaceutical SciencesNagoya City UniversityNagoyaJapan

Personalised recommendations